Read Original Release

Ties to drugmaker left out of postpartum depression drug study recap

Newly Published Results Show Investigational Treatment Brexanolone Consistently Reduced Depressive Symptoms Across Three Postpartum Depression Trials, Supporting Submission for FDA Approval

Our Review Summary

kangaroo care for newbornsAn injectable drug, brexanolone, showed some effectiveness in treating postpartum depression in two phase 3 double-blind randomized controlled trials including 247 women from 30 different research centers, according to research led by the University of North Carolina. Their research showed reductions in reported depression symptoms among study volunteers receiving either the drug or placebo (17 points for those on the drug, compared to a reduction of 12.8 points reduction for those on a placebo).

This study about a potential new drug is important, but the way it is reported leaves holes for the reader. The research was funded by the drug maker, Sage Therapeutics, and the two researchers quoted in the release have financial links to the drug manufacturer. The release should have given us more context about the amount of improvement, and been straightforward about the conflicts of interest.

 

Why This Matters

The American Psychological Association estimates that up to one-in-seven women in the US suffer from some form of postpartum depression, and this disorder can linger for some of them and interfere with their bonding with their child. Existing treatments, such as talk therapy and antidepressants are not always successful and may take weeks to improve the situation.

If approved by the FDA, the drug could be an advance in the treatment of postpartum depression which is common and sometimes serious.

Criteria

Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

The news release does not mention costs. While a new therapy may not have an established price, the release could have stated “no price is available for this drug.” What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications.

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

The release notes that  there was a reduction in depressive symptoms of 17 points for those on the drug, and 12.8 for those in the placebo group based on the Hamilton Depression Rating Scale. The absolute reduction in the rating scale is given for each group. This information would have been much more helpful if the release also clarified the magnitude of the scale and whether a 4.2-point difference is clinically meaningful.

Does the news release adequately explain/quantify the harms of the intervention?

Satisfactory

The release contains one somewhat vague sentence on harms.

The most common (≥10% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.

Readers would also be interested in details on whether the drug is safe for nursing infants. That’s not mentioned.

Does the news release seem to grasp the quality of the evidence?

Satisfactory

The double-blinded randomized trials are described in detail and readers are able to judge the quality of the evidence. The published study includes an important limitation of the research that’s not mentioned in the release: The trials assessed women for only 30 days; the effects of the treatment beyond 30 days are “unknown.”

Does the news release commit disease-mongering?

Satisfactory

There is no disease mongering. The release explains how common postpartum depression is worldwide.

Does the news release identify funding sources & disclose conflicts of interest?

Not Satisfactory

The release notes that Sage Therapeutics funded the research.

Sage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.

What the release doesn’t tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics.  This information was included in the studies published in the Lancet.

SM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina … DRR reports personal fees and has stock options in Sage Therapeutics….

Does the news release compare the new approach with existing alternatives?

Satisfactory

The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants — days rather than weeks.

Does the news release establish the availability of the treatment/test/product/procedure?

Satisfactory

The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year.

Does the news release establish the true novelty of the approach?

Satisfactory

The release notes that the new drug would be a novel treatment for postpartum depression, if approved.

Total Score: 8 of 10 Satisfactory

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.